News

Eyevensys reported data showing the efficacy and durability of EYS809, a dual-gene plasmid in development for the treatment of wet age-related macular degeneration (AMD).

At ARVO in New Orleans, Luxa Biotechnology shared an update on the progress of a Phase 1/2a clinical trial evaluating transplantation of RPESC-RPE-4W to treat dry age-related macular degeneration (AMD).

Researchers found in their analysis that visual impairment is associated with hallucinations, depression, agitation, and psychosis in patients with dementia, although, aging and comorbidities, among other factors, may be involved.

Amir H. Kashani, MD, PhD, joined us to share insights from his presentation at the 2023 ARVO meeting on optical coherence tomography and the assessment of cognitive impairment in Alzheimer's Disease and other related dementias.

Apellis Pharmaceuticals Inc. delivered an oral presentation at the ARVO Annual Meeting in New Orleans announcing their post hoc analyses from the Phase 3 OAKS and DERBY studies evaluating pegcetacoplan injection (Syfovre) for the treatment of geographic atrophy (GA).

Adverum Biotechnologies Inc. shared nonclinical data at ARVO 2023 in New Orleans that staggered, bilateral administration of Ixo-vec in NHPs was well tolerated with encouraging therapeutic activity and no signals of increased inflammation.

The team of Japanese researchers found that the choroidal MBR in the nasal region is correlated with systemic arterial stiffness and is significantly lower in patients with coronary artery multivessel disease.

Hydrogen-rich water may have a place in treatment of retinal degeneration. The team of investigators found that the hydrogen-rich water significantly improved the retinal blood flow (RBF) dysregulation in type 2 diabetic mice.

Thomas V. Johnson, MD, PhD recaps the research presentation "Retinal Engineering and RGC Replacement: Enhancing Integration of Transplanted RGCs at ARVO 2023.

The results indicated that SB15 had similar efficacy, safety, immunogenicity, and pharmacokinetics compared to aflibercept out to week 56 of the phase III trial.

In a mouse model of glaucoma, defective calcium clearance was seen as a characteristic feature of early damage to the retinal ganglion cells (RGC).

A team of researchers used gene expression, epigenetic, and gene regulation analyses to discover genes, pathways, and regulatory features relevant to age-related macular degeneration (AMD).

RetinAI announced their new partnership with Boehringer Ingelheim with the goal to improve patient outcomes in geographic atrophy (GA) by combining their respective expertise in artificial intelligence and retinal disease research.

Palatin Technologies, Inc. announced manuscript publication that summarizes data demonstrating the effects of PL8331 in two mouse models of retinal disease, experimental autoimmune uveoretinitis and diabetic retinopathy.

AVA-Net, a deep learning network, differentiated the changes in blood flow in healthy eyes compared with eyes of patients with diabetes with and without mild diabetic retinopathy.

Clearside Biomedical plans to open enrollment for their Phase 2b clinical trial of CLS-AX this quarter. Topline results are expected by the Q3 of 2024.

Complement Therapeutics GmbH secured financing to continue the development and complete a Phase Ib clinical proof of concept of its lead product CTx001, an AAV gene therapy for the treatment of GA secondary to dry-AMD.

Dr Ong and colleagues undertook a retrospective study of patients who underwent primary repair of uncomplicated RRDs at the Wilmer Eye Institute to examine the baseline, surgical, and postoperative characteristics that affect best-corrected VA (BCVA) outcomes.

Aviceda Therapeutics announced that the FDA has cleared the Investigational New Drug application for AVD-104, enabling the company to proceed with initiation of Phase 2 clinical trials.

New GA Won't Wait campaign partners Apellis Pharmaceuticals Inc. with actor Henry Winkler. The goal of this campaign is to raise awareness and educate older adults and their families about geographic atrophy (GA).

A large cohort study found no association between the first messenger RNA COVID-19 vaccinations and acute retinal vein occlusions.

Vance Thompson, MD, joined David Hutton, Managing Editor, Ophthalmology Times®, to provide an overview of his presentation on pearls for cataract surgery at the Real World Ophthalmology meeting.

Sally S. Ong, MD, shares the key takeaways from her presentation, Predictors of Poor Visual Outcome After Repair of Uncomplicated Rhegmatogenous Retinal Detachments, at the 11th Annual Vit-Buckle Society meeting.

Sean D. Adrean MD, FAAO, discusses the key takeaways from his presentation, Purposeful Pneumatic Induced Resorption of Submacular Fluid in Macula-off Retinal Detachments, at the 11th Annual Vit-Buckle Society meeting, April 13 to 15, in Las Vegas, Nevada.

Jennifer Lim, MD, FARVO joined David Hutton, Managing Editor, Ophthalmology Times®, to discuss her presentation on keratoprosthesis combined with vitrectomy surgery given at this year's Vit-Buckle Society meeting.

Study results see brolucizumab as a viable treatment for patients with neovascular age-related macular degeneration (nAMD) refractory to other anti-VEGF drugs.

Kala Pharmaceuticals KPI-012 receives FDA Fast Track designation as treatment for PCED with potential to treat retinitis pigmentosa and Stargardt disease.

J. Peter Campbell, MD, MPH, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss pediatric retina surgery and 3 key pearls to consider while performing the surgery.

Decreased cone density was a characteristic of the cases of multiple sclerosis (MS) that were evaluated. This finding may serve as a specific and sensitive method to detect and monitor the development and progression of MS.

The study compared eyes with retinopathy of prematurity (ROP) treated with laser to age-matched control eyes without ROP and found that the spherical equivalent was significantly more myopic in the eyes treated with laser.